

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-72. (canceled)

73. (Currently Amended) An amphiphilic drug-oligomer conjugate comprising a therapeutic compound comprising an enkephalin compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled to a hydrophilic moiety, and wherein the oligomer has the formula:



wherein

$m = 1$ to 6 ;

$n = 0$ or 1 ;

$x = 0, 3$ or 6 ;

$y = 1, 2, 3$ or 6 ;

$z = 2, 3, 7$ or 8 ;

$\text{A} =$ single bond, CO or $\text{CONHCH}_2\text{CH}_2$; and

$\text{E} = \text{OH}$ or OCH_2COOH .

74. (Canceled).

75. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the amphiphilic drug-oligomer conjugate exhibits the biological activity of the therapeutic compound without cleavage of the therapeutic compound from the oligomer.

76. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the amphiphilic drug-oligomer conjugate does not exhibit the biological activity of the therapeutic compound without cleavage of the therapeutic compound from the oligomer.

77. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the

lipophilic moiety is coupled to the hydrophilic moiety by a hydrolyzable bond.

78. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the lipophilic moiety is coupled to the hydrophilic moiety by a non-hydrolyzable bond.

79. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the lipophilic moiety is coupled to the hydrophilic moiety by a bond selected from the group consisting of: amide bond, carbamate bond, carbonate bond and ester bond.

80. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the oligomer is coupled to the therapeutic compound by a bond selected from the group consisting of amide bond, carbamate bond, carbonate bond and ester bond.

81. (Currently Amended) The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic compound is a peptide having enkephalin compound comprises~~ an added N-terminal residue selected from the group consisting of proline and alanine.

82. (Canceled).

83. (Currently Amended) The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic compound is an enkephalin compound is met-enkephalin-lys (SEQ ID NO:1) or an analog thereof.~~


84. (Currently Amended). The amphiphilic drug-oligomer conjugate of claim 73, wherein the ~~therapeutic enkephalin compound is met⁵-enkephalin (SEQ ID NO:48) or an analog thereof.~~

85. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the therapeutic compound is met-enkephalin-lys (SEQ ID NO:1) and the oligomer has the formula:



wherein m = 1, n = 0, A = CONHCH₂CH₂, E = OH, x = 0, y = 6, and z = 2.

86. (Previously Presented) The amphiphilic drug-oligomer conjugate of claim 73, wherein the therapeutic compound is met-enkephalin-lys (**SEQ ID NO:1**) and the oligomer has the formula:



wherein m = 1, n = 0, A = CONHCH₂CH₂, E = OH, x = 3, y = 2, and z = 7.